XPARAELIS
Market cap28mUSD
Dec 23, Last price
1.99EUR
1D
-4.33%
1Q
-61.73%
IPO
-83.42%
Name
Aelis Farma SA
Chart & Performance
P/E
—
P/S
3.01
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.10%
Rev. gr., 5y
195.83%
Revenues
9m
+137.70%
Net income
-5m
L-64.46%
CFO
-13m
L-3.56%
Profile
Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 9,054 137.70% | 3,809 -58.03% | 9,075 698.15% | ||||
Cost of revenue | 14,007 | 15,462 | 7,432 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (4,953) | (11,653) | 1,643 | ||||
NOPBT Margin | 18.10% | ||||||
Operating Taxes | 3 | 1,000 | 1,185 | ||||
Tax Rate | 72.12% | ||||||
NOPAT | (4,956) | (11,654) | 458 | ||||
Net income | (5,078) -64.46% | (14,288) -2,589.20% | 574 -127.52% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 127 | 25,544 | 35 | ||||
BB yield | -0.08% | -15.93% | |||||
| Debt | |||||||
Debt current | 1,094 | 814 | 1,156 | ||||
Long-term debt | 3,958 | 3,017 | 5,274 | ||||
Deferred revenue | 584 | 6,339 | |||||
Other long-term liabilities | 102 | 58 | 1,000 | ||||
Net debt | (15,178) | (30,780) | (18,280) | ||||
| Cash flow | |||||||
Cash from operating activities | (12,586) | (13,051) | 18,970 | ||||
CAPEX | (88) | (137) | (213) | ||||
Cash from investing activities | (88) | (86) | (212) | ||||
Cash from financing activities | (1,967) | 22,097 | 180 | ||||
FCF | (5,962) | (11,635) | 446 | ||||
| Balance | |||||||
Cash | 20,230 | 34,396 | 24,710 | ||||
Long term investments | 215 | ||||||
Excess cash | 19,777 | 34,421 | 24,256 | ||||
Stockholders' equity | (10,065) | (12,462) | (5,767) | ||||
Invested Capital | 27,408 | 36,050 | 18,047 | ||||
ROIC | 3.86% | ||||||
ROCE | 11.83% | ||||||
| EV | |||||||
Common stock shares outstanding | 12,899 | 11,840 | 9,593 | ||||
Price | 13.10 -3.25% | 13.54 | |||||
Market cap | 168,974 5.40% | 160,313 | |||||
EV | 153,796 | 129,533 | |||||
EBITDA | (4,785) | (11,583) | 1,678 | ||||
EV/EBITDA | |||||||
Interest | 159 | 112 | 140 | ||||
Interest/NOPBT | 8.52% | ||||||